Denali Therapeutics Inc. (FRA:4DN)

Germany flag Germany · Delayed Price · Currency is EUR
17.19
+1.14 (7.11%)
At close: Feb 20, 2026
Market Cap2.68B -17.9%
Revenue (ttm)n/a
Net Income-425.08M
EPS-2.48
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume30
Open17.19
Previous Close16.05
Day's Range17.19 - 17.19
52-Week Range10.17 - 21.14
Betan/a
RSI55.33
Earnings DateFeb 27, 2026

About Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme r... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 517
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4DN
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements